Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients

Heart

Volumn 92, Issue 12, 2006, Pages 1728-1731

  Struthers, Allan D ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE RECEPTOR; ALDOSTERONE RECEPTOR BLOCKER; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALSARTAN;

CLINICAL TRIAL; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; KIDNEY FUNCTION; MORTALITY; PRIORITY JOURNAL; REVIEW;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION;

EID: 33845223566     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.068668     Document Type: Review

References (15)

1. Farquharson C, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-75.
2. MacFadyen RJ, Lee AFC, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-18.
4. Pitt B, Remme W, Zannad F, et al. Eplerenone a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
5. Cohn JN, Tognoni G. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
6. McMurray JJV, Ostergren J, Svedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting inhibitors: the CHARM Added trial. Lancet 2003;362:767-71.
7. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003;349:1893-906.
8. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction, a systemic overview of data from individual patients. Lancet 2000;355:1575-81.
9. Juurlink DN, Mamdami MM, Lee DS, et al. Rates of hyperkalaemia after publication of the randomised aldactone evaluation study. N Engl J Med 2004;51:543-51.
10. Dimopoulos K, Salukhe TV, Coats AJS, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 2004;93:105-11.
11. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
12. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218-26.
13. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2002-31.
14. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
15. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.